Sauvie Inc. is a mission-driven biopharmaceutical company focused on sustainably building a premier immuno-oncology company. We signed an exclusive worldwide license with Rutgers University to develop and commercialize a pre-clinical stage nanobody bi-specific NK cell engager platform technology for oncology.
Our management team and board have extensive experience in operating in the start up as well as established private and public companies and developing and commercializing gold standard immuno-oncology brands.